Bavarian Nordic receives $228 million contract for smallpox vaccine
The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services, awarded the contract to Bavarian Nordic to maintain its stockpile of IMVAMUNE in case of a public health emergency. The first $110 million of the contract is secured, with the rest based on the availability of funds for 2014.
"We are grateful that the U.S. government has ordered another eight million doses of IMVAMUNE to maintain the 20 million doses stored in the U.S. Strategic National Stockpile, for use following a declared emergency in individuals of all ages with HIV infection or atopic dermatitis, including children, pregnant women, and nursing mothers," Anders Hedegaard, the president and CEO of Bavarian Nordic, said. "This order underscores the long-term relationship that exists between BARDA and Bavarian Nordic. As we work to develop a next-generation freeze-dried formulation of IMVAMUNE that offers a number of advantages, the current order goes a long way to bridge the gap by replenishing the inventory of the current frozen vaccine formulation. Also, it enables us to move the company forward in the development of further countermeasures to serve the government's needs."
Since 2010, Bavarian Nordic has delivered IMVAMUNE to the U.S. Strategic National Stockpile as part of a contract for 20 million doses of the vaccine. As of the end of 2012, 14.4 million doses were delivered to the stockpile. After the initial 20 million doses are delivered, the deliveries under the new contract will begin.
IMVAMUNE is being developed as a safer vaccine for smallpox for individuals with compromised immune systems, such as people with HIV or atopic dermatitis. The vaccine was the first successfully developed under the U.S. government program Project BioShield.